39635-10-4

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-2-hydroxybenzohydrazide is used as an intermediate in the synthesis of pharmaceuticals for its potential role in the development of drugs with antimicrobial and antifungal properties. Its ability to combat microbial infections makes it a valuable component in creating new medications.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Bromo-2-hydroxybenzohydrazide is utilized as a component in the formulation of products with antimicrobial and antifungal properties. This application helps in protecting crops from diseases and pests, thereby enhancing agricultural productivity.
Used in Antioxidant Applications:
5-Bromo-2-hydroxybenzohydrazide is studied for its potential use in the treatment of neurodegenerative diseases due to its antioxidant properties. Its ability to neutralize harmful free radicals may contribute to the development of therapies for conditions such as Alzheimer's and Parkinson's diseases.
Used in Research and Development:
As a reagent in organic synthesis, 5-Bromo-2-hydroxybenzohydrazide is employed in research and development laboratories. It aids scientists in conducting experiments and discovering new chemical reactions and compounds, further expanding its applications in the scientific community.

InChI:InChI=1/C7H7BrN2O2/c8-4-1-2-6(11)5(3-4)7(12)10-9/h1-3,11H,9H2,(H,10,12)

Upstream product

• 4068-76-2 5-bromo-2-hydroxy-benzoic acid methyl ester 
• 89-55-4 5-bromosalicyclic acid 

Downstream Products

• 92439-66-2 piperonal-(5-bromo-2-hydroxy-benzoylhydrazone) 
• 302909-34-8 5-bromo-2-hydroxy-benzoic acid-(4-chloro-benzylidenehydrazide) 
• 1257902-73-0 (Z)-3-(5'-bromosalicyloylhydrazinocarbonyl)prop-2-enoic acid 
• 1373438-68-6 5-bromo-2-(ethoxymethoxy)-N'-((1E)-1-(1H-indol-2-yl)ethylidene)benzohydrazide 
• 1350888-75-3 (E)-N'-(1-(1H-indol-2-yl)ethylidene)-5-bromo-2-hydroxybenzohydrazide 
• 1373438-08-4 (E)-N'-((1H-indol-2-yl)methylene)-5-bromo-2-hydroxybenzohydrazide 
• 1373438-10-8 (E)-N'-((1H-indol-2-yl)(phenyl)methylene)-5-bromo-2-hydroxybenzohydrazide 
• 1373438-11-9 C₂₂H₁₆BrN₃O₂ 
• 1373438-73-3 (E)-5-bromo-N'-(1-(5-bromo-1H-indol-2-yl)propylidene)-2-hydroxybenzohydrazide 
• 1350888-95-7 (E/Z)-5-bromo-N'-(1-(5-fluoro-1-methyl-1H-indol-2-yl)ethylidene)-2-hydroxybenzohydrazide 

Relevant academic research and scientific papers

SAR Studies on Aromatic Acylhydrazone-Based Inhibitors of Fungal Sphingolipid Synthesis as Next-Generation Antifungal Agents

Recently, the fungal sphingolipid glucosylceramide (GlcCer) synthesis has emerged as a highly promising new target for drug discovery of next-generation antifungal agents, and we found two aromatic acylhydrazones as effective inhibitors of GlcCer synthesis based on HTP screening. In the present work, we have designed libraries of new aromatic acylhydrazones, evaluated their antifungal activities (MIC80 and time-kill profile) against C. neoformans, and performed an extensive SAR study, which led to the identification of five promising lead compounds, exhibiting excellent fungicidal activities with very large selectivity index. Moreover, two compounds demonstrated broad spectrum antifungal activity against six other clinically relevant fungal strains. These five lead compounds were examined for their synergism/cooperativity with five clinical drugs against seven fungal strains, and very encouraging results were obtained; e.g., the combination of all five lead compounds with voriconazole exhibited either synergistic or additive effect to all seven fungal strains.

Synthesis, biological evaluation, and molecular docking studies of pyrazolyl-acylhydrazone derivatives as novel anticancer agents

A series of pyrazolyl-acylhydrazone derivatives (1e-20e) have been designed and synthesized and their biologic activities were also evaluated for telomerase inhibition and tumor cell antiproliferation. Among all the compounds, 12e showed the most potent activity in vitro, which inhibited the growth of MCF-7 and B16-F10 cell lines with IC50 values of 0.57 ± 0.03 and 0.49 ± 0.07 μM, respectively. Compound 12e also exhibited significant telomerase inhibitory activity (IC50 = 1.9 ± 0.43 μM). The result of flow cytometry demonstrated that compound 12e induced cell apoptosis. Docking simulation was performed to insert compound 12e into the crystal structure of telomerase at ATP binding site to determine the probable binding model. Based on the preliminary results, compound 12e with potent inhibitory activity in tumor growth may be a potential anticancer agent.